1
|
Nandi P, DeVore K, Wang F, Li S, Walker JD, Truong TT, LaPorte MG, Wipf P, Schlager H, McCleerey J, Paquette W, Columbres RCA, Gan T, Poh YP, Fromme P, Flint AJ, Wolf M, Huryn DM, Chou TF, Chiu PL. Mechanism of allosteric inhibition of human p97/VCP ATPase and its disease mutant by triazole inhibitors. Commun Chem 2024; 7:177. [PMID: 39122922 PMCID: PMC11316111 DOI: 10.1038/s42004-024-01267-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2024] [Accepted: 08/01/2024] [Indexed: 08/12/2024] Open
Abstract
Human p97 ATPase is crucial in various cellular processes, making it a target for inhibitors to treat cancers, neurological, and infectious diseases. Triazole allosteric p97 inhibitors have been demonstrated to match the efficacy of CB-5083, an ATP-competitive inhibitor, in cellular models. However, the mechanism is not well understood. This study systematically investigates the structures of new triazole inhibitors bound to both wild-type and disease mutant forms of p97 and measures their effects on function. These inhibitors bind at the interface of the D1 and D2 domains of each p97 subunit, shifting surrounding helices and altering the loop structures near the C-terminal α2 G helix to modulate domain-domain communications. A key structural moiety of the inhibitor affects the rotameric conformations of interacting side chains, indirectly modulating the N-terminal domain conformation in p97 R155H mutant. The differential effects of inhibitor binding to wild-type and mutant p97 provide insights into drug design with enhanced specificity, particularly for oncology applications.
Collapse
Affiliation(s)
- Purbasha Nandi
- School of Molecular Sciences, Arizona State University, Tempe, AZ, USA
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, USA
- Biology Department, Brookhaven National Laboratory, Upton, NY, USA
| | - Kira DeVore
- School of Molecular Sciences, Arizona State University, Tempe, AZ, USA
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, USA
| | - Feng Wang
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA
| | - Shan Li
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA
| | - Joel D Walker
- University of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Thanh Tung Truong
- University of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA
- Faculty of Pharmacy, Phenikaa University, Hanoi, Vietnam
| | - Matthew G LaPorte
- University of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Peter Wipf
- University of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Chemistry, University of Pittsburgh, Pittsburgh, PA, USA
| | | | - John McCleerey
- Curia Global, Albany, NY, USA
- Graduate School of Arts and Sciences, Boston University, Boston, MA, USA
| | | | - Rod Carlo A Columbres
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA
- Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA
| | - Taiping Gan
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA
| | - Yu-Ping Poh
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, USA
- Biodesign Center for Mechanism of Evolution, Arizona State University, Tempe, AZ, USA
| | - Petra Fromme
- School of Molecular Sciences, Arizona State University, Tempe, AZ, USA
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, USA
| | - Andrew J Flint
- Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | | | - Donna M Huryn
- University of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA
- Department of Chemistry, University of Pennsylvania, Philadelphia, PA, USA
| | - Tsui-Fen Chou
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
- Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, CA, USA.
| | - Po-Lin Chiu
- School of Molecular Sciences, Arizona State University, Tempe, AZ, USA.
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, USA.
| |
Collapse
|
2
|
Ma C, Wu D, Chen Q, Gao N. Structural dynamics of AAA + ATPase Drg1 and mechanism of benzo-diazaborine inhibition. Nat Commun 2022; 13:6765. [PMID: 36351914 PMCID: PMC9646744 DOI: 10.1038/s41467-022-34511-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 10/27/2022] [Indexed: 11/11/2022] Open
Abstract
The type II AAA + ATPase Drg1 is a ribosome assembly factor, functioning to release Rlp24 from the pre-60S particle just exported from nucleus, and its activity in can be inhibited by a drug molecule diazaborine. However, molecular mechanisms of Drg1-mediated Rlp24 removal and diazaborine-mediated inhibition are not fully understood. Here, we report Drg1 structures in different nucleotide-binding and benzo-diazaborine treated states. Drg1 hexamers transits between two extreme conformations (planar or helical arrangement of protomers). By forming covalent adducts with ATP molecules in both ATPase domain, benzo-diazaborine locks Drg1 hexamers in a symmetric and non-productive conformation to inhibits both inter-protomer and inter-ring communication of Drg1 hexamers. We also obtained a substrate-engaged mutant Drg1 structure, in which conserved pore-loops form a spiral staircase to interact with the polypeptide through a sequence-independent manner. Structure-based mutagenesis data highlight the functional importance of the pore-loop, the D1-D2 linker and the inter-subunit signaling motif of Drg1, which share similar regulatory mechanisms with p97. Our results suggest that Drg1 may function as an unfoldase that threads a substrate protein within the pre-60S particle.
Collapse
Affiliation(s)
- Chengying Ma
- grid.11135.370000 0001 2256 9319State Key Laboratory of Membrane Biology, Peking-Tsinghua Joint Center for Life Sciences, School of Life Sciences, Peking University, 100871 Beijing, China ,Changping Laboratory, 102206 Beijing, China
| | - Damu Wu
- grid.11135.370000 0001 2256 9319State Key Laboratory of Membrane Biology, Peking-Tsinghua Joint Center for Life Sciences, School of Life Sciences, Peking University, 100871 Beijing, China
| | - Qian Chen
- grid.11135.370000 0001 2256 9319State Key Laboratory of Membrane Biology, Peking-Tsinghua Joint Center for Life Sciences, School of Life Sciences, Peking University, 100871 Beijing, China
| | - Ning Gao
- grid.11135.370000 0001 2256 9319State Key Laboratory of Membrane Biology, Peking-Tsinghua Joint Center for Life Sciences, School of Life Sciences, Peking University, 100871 Beijing, China ,Changping Laboratory, 102206 Beijing, China ,grid.11135.370000 0001 2256 9319National Biomedical Imaging Center, Peking University, 100871 Beijing, China
| |
Collapse
|